1558 Stock Overview
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$9.66 |
| 52 Week High | HK$13.30 |
| 52 Week Low | HK$7.91 |
| Beta | 0.079 |
| 1 Month Change | 6.39% |
| 3 Month Change | 1.26% |
| 1 Year Change | 1.79% |
| 3 Year Change | 62.35% |
| 5 Year Change | -53.45% |
| Change since IPO | 32.87% |
Recent News & Updates
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Strong Profits May Be Masking Some Underlying Issues
Oct 07
Should You Be Adding YiChang HEC ChangJiang Pharmaceutical (HKG:1558) To Your Watchlist Today?
Sep 19Recent updates
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Strong Profits May Be Masking Some Underlying Issues
Oct 07Should You Be Adding YiChang HEC ChangJiang Pharmaceutical (HKG:1558) To Your Watchlist Today?
Sep 19YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%
May 29Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?
Apr 23YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30Shareholder Returns
| 1558 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0.2% | 0.9% | 2.1% |
| 1Y | 1.8% | -9.1% | 17.6% |
Return vs Industry: 1558 exceeded the Hong Kong Pharmaceuticals industry which returned -9.1% over the past year.
Return vs Market: 1558 underperformed the Hong Kong Market which returned 17.6% over the past year.
Price Volatility
| 1558 volatility | |
|---|---|
| 1558 Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 3.9% |
Stable Share Price: 1558 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1558's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 4,891 | Juncai Jiang | www.hec-changjiang.com |
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, sells, and markets pharmaceutical products in the therapeutic areas of anti-infection, endocrine and metabolic, and other diseases in the People’s Republic of China. It manufactures and sells active pharmaceutical ingredients; researches and develops pharmaceutical products, and medical devices and drugs, as well as biotechnology; and provides marketing and medical consulting services.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Fundamentals Summary
| 1558 fundamental statistics | |
|---|---|
| Market cap | HK$8.50b |
| Earnings (TTM) | HK$1.75b |
| Revenue (TTM) | HK$5.89b |
4.9x
P/E Ratio1.4x
P/S RatioIs 1558 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1558 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.54b |
| Cost of Revenue | CN¥1.17b |
| Gross Profit | CN¥4.37b |
| Other Expenses | CN¥2.72b |
| Earnings | CN¥1.65b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.87 |
| Gross Margin | 78.90% |
| Net Profit Margin | 29.74% |
| Debt/Equity Ratio | 23.9% |
How did 1558 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 00:06 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Ling Zhang | China Merchants Securities (HK) Co., Ltd |
| null null | CMB International Securities Limited |